Literature DB >> 8629607

Determinants of mortality from cystic fibrosis in Canada, 1970-1989.

M Corey1, V Farewell.   

Abstract

The frequency, prevalence, and mortality patterns of cystic fibrosis were analyzed in 3,795 patients documented in the Canadian Patient Data Registry in 1970-1989. Cystic fibrosis frequency in the 1970-1979 birth cohort was virtually identical to the commonly quoted 1 in 2,500. In 1985-1989, median survival age was 36.7 years for males and 27.8 years for females, compared with 26.6 and 19.7, respectively, in 1970-1974. However, there were significant regional differences when Canada was divided into the four regions, East, Quebec, Ontario, and West. In Quebec, patients were younger at diagnosis and until recently had greater mortality than patients in other regions, which suggests more severe disease; dramatically improved survival in the 1980s coincided with a change from a restricted fat diet to a high fat diet. Improved survival in Ontario in the 1970s accompanied this change in dietary therapy, which may also account for good survival throughout the study period in the East. The West showed gradually improving survival, similar to that reported in other parts of the world. Proportional hazards analysis showed pulmonary function to be the best predictor of survival. Poorer survival in females was associated with poorer weight, but the interrelation of declining pulmonary function, weight maintenance, sex, and mortality requires further study. The effect of pulmonary colonization with Pseudomonas aeruginosa was confounded with degree of pulmonary dysfunction, but colonization with Burkholderia cepacia (previously Pseudomonas cepacia) was associated with increased mortality at all levels of pulmonary function.

Entities:  

Mesh:

Year:  1996        PMID: 8629607     DOI: 10.1093/oxfordjournals.aje.a008664

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  87 in total

1.  Identification of hopanoid biosynthesis genes involved in polymyxin resistance in Burkholderia multivorans.

Authors:  Rebecca J Malott; Barbara R Steen-Kinnaird; Tracy D Lee; David P Speert
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Kathleen M Thickett; David Honeybourne; Martin C J Maiden; John R Govan; David P Speert; John J Lipuma; Peter Vandamme; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.

Authors:  Juyan Zhou; Yunhua Chen; Setareh Tabibi; Luis Alba; Elizabeth Garber; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

4.  Distribution and expression of the ZmpA metalloprotease in the Burkholderia cepacia complex.

Authors:  S Gingues; C Kooi; M B Visser; B Subsin; P A Sokol
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

5.  Development of a species-specific fur gene-based method for identification of the Burkholderia cepacia complex.

Authors:  Karlene H Lynch; Jonathan J Dennis
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

Review 6.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

7.  Gender differences in outcomes of patients with cystic fibrosis.

Authors:  Cayce L Harness-Brumley; Alan C Elliott; Daniel B Rosenbluth; Deepa Raghavan; Raksha Jain
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

8.  Refractory Burkholderia cepacia bacteraemia from a consolidation pneumonia lasting more than 7 weeks, successfully treated with systemic antibiotics and nebulised meropenem.

Authors:  Bryan Albert Lim; Adelaine Lopez; Joseph Adrian Buensalido
Journal:  BMJ Case Rep       Date:  2019-08-02

9.  Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.

Authors:  M R Shreve; S Butler; H J Kaplowitz; H R Rabin; D Stokes; M Light; W E Regelmann
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 10.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.